# Reinhard Dummer

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/reinhard-dummer/

## Facts

| Field | Value |
| --- | --- |
| Citations | 131,093 |
| Field | Melanoma and MAPK Pathways |
| h-index | 154 |
| i10-index | 866 |
| Last Known Institution | University of Zurich |
| OpenAlex ID | https://openalex.org/A5089297467 |
| ORCID iD | https://orcid.org/0000-0002-2279-6906 |
| Works | 2,793 |

## Researcher papers

Showing 12 of 22.

- [Genomic correlates of response to CTLA-4 blockade in metastatic melanoma](https://scholariq.org/papers/genomic-correlates-of-response-to-ctla-4-blockade-in-metastatic-melanoma/)
- [Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)](https://scholariq.org/papers/revisions-to-the-staging-and-classification-of-mycosis-fungoides-and-sezary/)
- [Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma](https://scholariq.org/papers/completion-dissection-or-observation-for-sentinel-node-metastasis-in-melanoma/)
- [Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study](https://scholariq.org/papers/epacadostat-plus-pembrolizumab-versus-placebo-plus-pembrolizumab-in-patients/)
- [Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/overall-survival-benefit-with-tebentafusp-in-metastatic-uveal-melanoma/)
- [Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer](https://scholariq.org/papers/clinical-end-points-and-response-criteria-in-mycosis-fungoides-and-sezary/)
- [Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial](https://scholariq.org/papers/mogamulizumab-versus-vorinostat-in-previously-treated-cutaneous-t-cell-lymphoma/)
- [Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines](https://scholariq.org/papers/diagnosis-and-treatment-of-basal-cell-carcinoma-european-consensus-based/)
- [TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)](https://scholariq.org/papers/tnm-classification-system-for-primary-cutaneous-lymphomas-other-than-mycosis/)
- [Thalassemia Syndromes](https://scholariq.org/papers/thalassemia-syndromes/)
- [European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas](https://scholariq.org/papers/european-organization-for-research-and-treatment-of-cancer-and-international/)
- [European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017](https://scholariq.org/papers/european-organisation-for-research-and-treatment-of-cancer-consensus/)

## Researcher topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cutaneous lymphoproliferative disorders research](https://scholariq.org/topics/cutaneous-lymphoproliferative-disorders-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [University of Zurich](https://scholariq.org/institutions/university-of-zurich/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.